The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5

AIDS

Volumn 22, Issue 3, 2008, Pages 430-432

  Lin, Yea Lih ^a   Mettling, Clément ^a   Portalès, Pierre ^a   Rouzier, Régine ^b   Clot, Jacques ^a   Reynes, Jacques ^c   Corbeau, Pierre ^a  

^a HÔPITAL SAINT ELOI   (France)

^b Centre CAP   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLACEBO; RANTES; VICRIVIROC;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOMODULATION; INFECTION RESISTANCE; INTERNALIZATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY;

CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL5; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CCR5; RNA, MESSENGER;

EID: 38149067432     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f46a6f     Document Type: Article

References (16)

1. Reynes J, Portales P, Segondy M, Baillat V, André P, Avinens O, et al. CD4RT cell surface CCR5 density as a determining factor of viral load in HIV-1-infected individuals. J Infect Dis 2000; 181:927-932.
2. Lin Y-L, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 2002; 99:15590-15595.
3. Reynes J, Baillat V, Portalès P, Clot J, Corbeau P. Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy. JAMA 2004; 291:46.
4. Gervaix A, Nicolas J, Portales P, Posfay-Barbe K, Wyler CA, Segondy M, et al. Response to treatment and disease progression linked to CD4R T cell surface CCR5 density in HIV-1 vertical infection. J Infect Dis 2002; 185:1055-1061.
5. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Avinens O, et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001; 15:1627-1634.
6. Desmetz C, Lin Y-L, Mettling C, Portalès P, Rabesandratana H, Clot J, Corbeau P. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 2006; 119:551-561.
7. Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, Mosier DE. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol 2001; 75:661-671.
8. Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, Marsh M. Endocytosis and recycling of the HIV coreceptor CCR5. J Cell Biol 2000; 151:1281-1294.
9. Wetzel MA, Steele AD, Eisenstein TK, Adler MW, Henderson EE, Rogers TJ. Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN9-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol 2000; 165:6519-6524.
10. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. Ann Rheum Dis 2002; 61:834-837.
11. Zhao D, Pritts EA, Chao VA, Savouret JF, Taylor RN. Dioxin stimulates RANTES expression in an in-vitro model of endometriosis. Mol Hum Reprod 2002; 8:849-854.
12. Li QQ, Burt DR, Bever CT. Glatiramer acetate inhibition of tumor necrosis factor-alpha-induced RANTES expression and release from U-251 MG human astrocytic cells. J Neurochem 2001; 77:1208-1217.
13. Zhao D, Lebovic DI, Taylor RN. Long-term progestin treatment inhibits RANTES (regulated on activation, normal T cell expressed and secreted) gene expression in human endometrial stomal cells. J Clin Endocrinol Metab 2002; 87:2514-2519.
14. Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol 2003; 3:225-232.
15. Mak NK, Leung CY, Wei XY, Shen XL, Wong RN, Leung KN, Fung MC. Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells. Biochem Pharmacol 2004; 67:167-174.
16. Lin Y-L, Mettling C, Portales P, Réant B, Clot J, Corbeau P. G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes. J Virol 2005; 79:7938-7941.